jens juul holst glp 1 Dr. on GLP-1’s Life-Changing Impact on Metabolic Health Historien om GLP-1 af Jens
Description
doi: 10.1038/s41387-024-00268-4

Glucagon-like peptide-1 (GLP-1) agonists are the latest evolution of drugs that are reshaping the way we treat diabetes, obesity, and other forms of addiction.

Nicholas Peiper | 11 comments on LinkedIn

Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s

Recently, researchers have observed that conditions like diabetes, obesity, poor vascular health and inflammation all raise the risk of dementia
